1. Camassei, F.D., Cozza, R., Acquaviva, A., Jenkner, A., Ravà, L., Gareri, R., Donfrancesco, A., Bosman, C., Vadalà, P., Hadjistilianou, T., Boldrini, R., 2003. Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness. Invest. Ophthalmol. Vis. Sci., 44(6):2399–2403. [doi:10.1167/iovs.02-0934]
2. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T., Selby, P.J., 2002. High-dose chemotherapy with haematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med., 348(19):1175–1183.
3. Gabrielson, E.W., Pinn, M.L., Testa, J.R., Kuhajda, F.P., 2001. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin. Cancer Res., 7(1):153–157.
4. Gansler, T.S., Hardman, W., Hunt, D.A., Schaffel, S., Hennigar, R.A., 1997. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol., 28(6):686–692. [doi:10.1016/S0046-8177(97)90177-5]
5. Garber, K., 2006. Energy deregulation: licensing tumors to grow. Science, 312(5777):1158–1159. [doi:10.1126/science.312.5777.1158]